For our outcome analysis in AML, we first compared STAG2-mutant AML to cohesin-WT cases separated into cohesin-WT AML associated with myelodysplasia-related changes (thereafter referred to as “AML-MR”) and cohesin-WT AML not associated with myelodysplasia-related changes (thereafter referred to as “AML-non-MR”) according to the WHO 2022 classification. The gene discussed is STAG2; the disease is Myelodysplasia.